{"id":510512,"date":"2021-07-07T16:08:14","date_gmt":"2021-07-07T20:08:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/"},"modified":"2021-07-07T16:08:14","modified_gmt":"2021-07-07T20:08:14","slug":"agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/","title":{"rendered":"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021"},"content":{"rendered":"
\n

LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) — Agenus<\/a> (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven O\u2019Day, MD, Chief Medical Officer of Agenus, will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 titled \u201cNovel Mechanisms and Strategies for Addressing PD-(L)1 Refractory\/Resistant Tumors.\u201d<\/p>\n

The panel will take place on Wednesday, July 14, 2021, from 4:20 p.m. to 5:20 p.m. ET. The event will be webcast live and may be accessed on the Company’s website at https:\/\/investor.agenusbio.com\/events-and-presentations<\/a>.<\/p>\n

\n
\n About Agenus<\/u>
\n <\/strong>
\n
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.<\/p>\n

\n
\n Contact<\/u>
\n <\/strong>
\n
\n Agenus Investor Relations<\/strong>
\n
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com<\/a><\/p>\n

\n Agenus Media Relations<\/strong>
\n
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven O\u2019Day, MD, Chief Medical Officer of Agenus, will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 titled \u201cNovel Mechanisms and Strategies for Addressing PD-(L)1 Refractory\/Resistant Tumors.\u201d The panel will take place on Wednesday, July 14, 2021, from 4:20 p.m. to 5:20 p.m. ET. The event will be webcast live and may be accessed on the Company’s website at https:\/\/investor.agenusbio.com\/events-and-presentations. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that … <\/p>\n

Continue reading “Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510512","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAgenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven O\u2019Day, MD, Chief Medical Officer of Agenus, will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 titled \u201cNovel Mechanisms and Strategies for Addressing PD-(L)1 Refractory\/Resistant Tumors.\u201d The panel will take place on Wednesday, July 14, 2021, from 4:20 p.m. to 5:20 p.m. ET. The event will be webcast live and may be accessed on the Company’s website at https:\/\/investor.agenusbio.com\/events-and-presentations. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that … Continue reading "Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T20:08:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021\",\"datePublished\":\"2021-07-07T20:08:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/\"},\"wordCount\":267,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/\",\"name\":\"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=\",\"datePublished\":\"2021-07-07T20:08:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/","og_locale":"en_US","og_type":"article","og_title":"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 - Market Newsdesk","og_description":"LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven O\u2019Day, MD, Chief Medical Officer of Agenus, will participate in a panel discussion at the William Blair Biotech Focus Conference 2021 titled \u201cNovel Mechanisms and Strategies for Addressing PD-(L)1 Refractory\/Resistant Tumors.\u201d The panel will take place on Wednesday, July 14, 2021, from 4:20 p.m. to 5:20 p.m. ET. The event will be webcast live and may be accessed on the Company’s website at https:\/\/investor.agenusbio.com\/events-and-presentations. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that … Continue reading \"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T20:08:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021","datePublished":"2021-07-07T20:08:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/"},"wordCount":267,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/","name":"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=","datePublished":"2021-07-07T20:08:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3Njg4OSM0Mjg3MjgwIzIwMjAwNDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-participate-in-resistance-focused-oncology-panel-at-the-william-blair-biotech-focus-conference-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510512"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510512\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}